Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models
Yuanjing Liu,
Jean-Cosme Dodart,
Helene Tran,
Shaunna Berkovitch,
Maurine Braun,
Michael Byrne,
Ann F. Durbin,
Xiao Shelley Hu,
Naoki Iwamoto,
Hyun Gyung Jang,
Pachamuthu Kandasamy,
Fangjun Liu,
Kenneth Longo,
Jörg Ruschel,
Juili Shelke,
Hailin Yang,
Yuan Yin,
Amy Donner,
Zhong Zhong,
Chandra Vargeese () and
Robert H. Brown
Additional contact information
Yuanjing Liu: Wave Life Sciences Ltd.
Jean-Cosme Dodart: Wave Life Sciences Ltd.
Helene Tran: University of Massachusetts
Shaunna Berkovitch: Wave Life Sciences Ltd.
Maurine Braun: Wave Life Sciences Ltd.
Michael Byrne: Wave Life Sciences Ltd.
Ann F. Durbin: Wave Life Sciences Ltd.
Xiao Shelley Hu: Wave Life Sciences Ltd.
Naoki Iwamoto: Wave Life Sciences Ltd.
Hyun Gyung Jang: Wave Life Sciences Ltd.
Pachamuthu Kandasamy: Wave Life Sciences Ltd.
Fangjun Liu: Wave Life Sciences Ltd.
Kenneth Longo: Wave Life Sciences Ltd.
Jörg Ruschel: Wave Life Sciences Ltd.
Juili Shelke: Wave Life Sciences Ltd.
Hailin Yang: Wave Life Sciences Ltd.
Yuan Yin: Wave Life Sciences Ltd.
Amy Donner: Wave Life Sciences Ltd.
Zhong Zhong: Wave Life Sciences Ltd.
Chandra Vargeese: Wave Life Sciences Ltd.
Robert H. Brown: University of Massachusetts
Nature Communications, 2021, vol. 12, issue 1, 1-15
Abstract:
Abstract A large G4C2-repeat expansion in C9orf72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Neuronal degeneration associated with this expansion arises from a loss of C9orf72 protein, the accumulation of RNA foci, the expression of dipeptide repeat (DPR) proteins, or all these factors. We report the discovery of a new targeting sequence that is common to all C9orf72 transcripts but enables preferential knockdown of repeat-containing transcripts in multiple cellular models and C9BAC transgenic mice. We optimize stereopure oligonucleotides that act through this site, and we demonstrate that their preferential activity depends on both backbone stereochemistry and asymmetric wing design. In mice, stereopure oligonucleotides produce durable depletion of pathogenic signatures without disrupting protein expression. These oligonucleotides selectively protect motor neurons harboring C9orf72-expansion mutation from glutamate-induced toxicity. We hypothesize that targeting C9orf72 with stereopure oligonucleotides may be a viable therapeutic approach for the treatment of C9orf72-associated neurodegenerative disorders.
Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (2)
Downloads: (external link)
https://www.nature.com/articles/s41467-021-21112-8 Abstract (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-21112-8
Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/
DOI: 10.1038/s41467-021-21112-8
Access Statistics for this article
Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie
More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().